For hypertensive patients with CHD, ischemic stroke, or peripheral vascular disease, it is recommended to take 75–100 mg/day of aspirin

The gap

Evidence profile

Sourced from the recommendations of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 3 journals. Those papers have been cited 46 times in total.

Supporting evidence — 3 representative gaps

• Clinical practice guideline for the management of hypertension in China (2024) · Chinese Medical Journal · cited 45× · doi

  For hypertensive patients with CHD, ischemic stroke, or peripheral vascular disease, it is recommended to take 75–100  mg/day of aspirin for long-term secondary pre- vention (1A). For those aged 40–65 years with hypertension and cardiovas- cular risk, if the risk of bleeding is not high, low-dose aspirin (75–100  mg/day) can be considered for primary prevention (2B). For high-risk groups for bleeding (e.g., history of gastroin- testinal bleeding, recent cerebral hemorrhage, use of drugs that increase bleeding risk, uncontrolled hypertension), aspirin for primary prevention is not recommended (2C).

  generalrecommendations
  Keywords: risk bleeding aspirin recommended hypertension high primary prevention hypertensive patients ischemic stroke peripheral vascular disease
• Egyptian Society of Cardiology national advisory statement revisiting antiplatelet therapy: insights from E. S. C. 2025 hot-line trials (2026) · The Egyptian Heart Journal · doi

  N Engl J Med. 2025 N Engl J Med. 2025 ischemic risk Early aspirin discontinuation after 1 month may be reasonable in low-risk MI with complete revascularization using third-generation DES Immediate aspirin withdrawal (≤ 4 days) is not recommended Eur Heart J. 2026 J Am Coll Cardiol. 2025 ESC Congress 2025; Twice-daily aspirin should not be used routinely Twice-daily clopidogrel for 1 month may be considered as a cost-effective alternative to ticagrelor in selected STEMI patients IV cangrelor may be considered when oral absorption is unreliable TARGET-FIRST [7] NEO-MINDSET [8] ANDAMAN [9] TADCLOT [10] DAPT-SHOCK- AMI [11] TOP-CABG [12] Eur Heart J. 2025 TACSI [13] N Engl J Med. 2025 TAILORED-CHIP [14] Eur Heart J. 2026 PARTHENOPE [15] AQUATIC [16] J Am Coll Cardiol. 2025 N Engl J Med. 2025 Three-month DAPT followed by aspirin is reasonable for most ACS patients undergoing isolated CABG Aspirin monotherapy may be preferred in ACS patients at high bleeding risk undergoing isolated CABG Routine escalation–de-escalation strategies in complex PCI are not recommended; standard DAPT should remain the default approach unless individualized risk assessment supports an alternative strategy A score-guided approach to DAPT duration may be considered when institutional systems allow Aspirin should not be added to OAC unless there is a compelling indication such as recent stenting

  generalrecommendations
  Keywords: aspirin engl risk dapt month heart considered patients cabg reasonable recommended coll cardiol twice daily
• Optimal antithrombotic therapy after transcatheter aortic valve replacement: a comprehensive review (2025) · Frontiers in Cardiovascular Medicine · cited 1× · doi

  2A 2B 2B 3 B B B B Aspirin 75–100 mg daily is reasonable in the absence of other indications for oral anticoagulants. For patients at low risk of bleeding, DAPT with aspirin 75–100 mg and clopidogrel 75 mg may be reasonable for 3– 6 months after valve implantation. For patients at low risk of bleeding, anticoagulation with a VKA to achieve an INR of 2.5 may be reasonable for at least 3 months after valve implantation. Treatment with low-dose rivaroxaban (10 mg daily) plus aspirin (75–100 mg) is contraindicated in the absence of other indications for oral anticoagulants. ESC/EACTS 2021 guidelines (2) 1 1 NA 3 A B NA B Lifelong SAPT is recommended after TAVI in patients with no baseline indication for OAC. Lifelong OAC is recommended for patients who have other indications for OAC. If recent coronary stenting (<3 months) and no concomitant indications for OAC, consider DAPT for 1–6 months and then SAPT. If recent coronary stenting (<3 months) and concomitant indication for OAC, continue lifelong OAC and consider SAPT for 1–6 months. Routine use of OAC is not recommended after TAVI in patients with no baseline indication for OAC. ACC, American College of Cardiology; AHA, American Heart Association; DAPT, dual antiplatelet therapy; EACTS, European Association for Cardio-Thoracic Surgery; ESC, European Society of Cardiology; INR, international normalized ratio; NA, not available; OAC, oral anticoagulation; SAPT, single antiplatelet therapy; VKA, vitamin K antagonist.

  generalrecommendations
  Keywords: months patients indications sapt aspirin reasonable oral dapt lifelong recommended indication daily absence anticoagulants risk

Questions about this gap